PI3K inhibitors as novel cancer therapies: Implications for cardiovascular medicine

Journal of Cardiac Failure

Volumn 19, Issue 4, 2013, Pages 268-282

  McLean, Brent A ^a   Zhabyeyev, Pavel ^a   Pituskin, Edith ^a   Paterson, Ian ^a   Haykowsky, Mark J ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cardio oncology; cardiotoxicity; kinase inhibitors; Phosphatidylinositol 3 kinase

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BGT 226; BISOPROLOL; BUPARLISIB; BYL 719; DOBUTAMINE; G PROTEIN COUPLED RECEPTOR; GDC 0032; GDC 0980; GLUCOSE TRANSPORTER 4; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERINDOPRIL; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PKI 587; RAPAMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; WORTMANNIN; XL 147; XL 765;

ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILDHOOD CANCER; COLORECTAL CANCER; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; ENDOCYTOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOTHELIUM CELL; EXERCISE; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HEART ELECTROPHYSIOLOGY; HEART FUNCTION; HEART HYPERTROPHY; HEART PROTECTION; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIFESTYLE MODIFICATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; METABOLIC REGULATION; NEGATIVE FEEDBACK; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTE AGGREGATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION;

EID: 84876240706     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2013.02.005     Document Type: Review

References (176)

1. S.F. Wong, and H. Mirshahidi Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners Ann Pharmacother 45 2011 787 797
2. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, and L. Fehrenbacher Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 719 726
3. T. Force, D.S. Krause, and R.A. van Etten Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 2007 332 344
4. A. Garcia-Alvarez, X. Garcia-Albeniz, J. Esteve, M. Rovira, and X. Bosch Cardiotoxicity of tyrosine-kinase-targeting drugs Cardiovasc Hematol Agents Med Chem 8 2010 11 21
5. T. Force, and K.L. Kolaja Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat Rev Drug Discov 10 2011 111 126
6. L.A. Smyth, and I. Collins Measuring and interpreting the selectivity of protein kinase inhibitors J Chem Biol 2 2009 131 151
7. T.T. Junttila, R.W. Akita, K. Parsons, C. Fields, G.D. Lewis Phillips, and L.S. Friedman Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 Cancer Cell 15 2009 429 440
8. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, and B. Bilanges The emerging mechanisms of isoform-specific PI3K signalling Nat Rev Mol Cell Biol 11 2010 329 341
9. G.Y. Oudit, and J.M. Penninger Cardiac regulation by phosphoinositide 3-kinases and PTEN Cardiovasc Res 82 2009 250 260
10. M. Andjelkovic, D.R. Alessi, R. Meier, A. Fernandez, N.J. Lamb, and M. Frech Role of translocation in the activation and function of protein kinase B J Biol Chem 272 1997 31515 31524
11. M.A. Lemmon Membrane recognition by phospholipid-binding domains Nat Rev Mol Cell Biol 9 2008 99 111
12. P. Hu, A. Mondino, E.Y. Skolnik, and J. Schlessinger Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85 Mol Cell Biol 13 1993 7677 7688
13. O. Vadas, J.E. Burke, X. Zhang, A. Berndt, and R.L. Williams Structural basis for activation and inhibition of class I phosphoinositide 3-kinases Sci Signal 4 2011 re2
14. L. Bi, I. Okabe, D.J. Bernard, A. Wynshaw-Boris, and R.L. Nussbaum Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase J Biol Chem 274 1999 10963 10968
15. T. Shioi, P.M. Kang, P.S. Douglas, J. Hampe, C.M. Yballe, and J. Lawitts The conserved phosphoinositide 3-kinase pathway determines heart size in mice EMBO J 19 2000 2537 2548
16. J.R. McMullen, F. Amirahmadi, E.A. Woodcock, M. Schinke-Braun, R.D. Bouwman, and K.A. Hewitt Protective effects of exercise and phosphoinositide 3-kinas (p110alpha) signaling in dilated and hypertrophic cardiomyopathy Proc Natl Acad Sci U S A 104 2007 612 617
17. R.C. Lin, K.L. Weeks, X.M. Gao, R.B. Williams, B.C. Bernardo, and H. Kiriazis PI3 (p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA Arterioscler Thromb Vasc Biol 30 2010 724 732
18. M. Graupera, J. Guillermet-Guibert, L.C. Foukas, L.K. Phng, R.J. Cain, and A. Salpekar Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration Nature 453 2008 662 666
19. N. Yano, A. Tseng, T.C. Zhao, J. Robbins, J.F. Padbury, and Y.T. Tseng Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility - a new transgenic model Am J Physiol Heart Circ Physiol 295 2008 H1690 H1694
20. C.Y. Wu, Z. Jia, W. Wang, L.M. Ballou, Y.P. Jiang, and B. Chen PI3Ks maintain the structural integrity of T-tubules in cardiac myocytes PLoS One 6 2011 e24404
21. L. Bi, I. Okabe, D.J. Bernard, and R.L. Nussbaum Early embryonic lethality in mice deficient in the p110beta catalytic subunit of Pi 3-kinase Mamm Genome 13 2002 169 172
22. E. Hirsch, V.L. Katanaev, C. Garlanda, O. Azzolino, L. Pirola, and L. Silengo Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation Science 287 2000 1049 1053
23. M.A. Crackower, G.Y. Oudit, I. Kozieradzki, R. Sarao, H. Sun, and T. Sasaki Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways Cell 110 2002 737 749
24. D. Guo, Z. Kassiri, R. Basu, F.L. Chow, V. Kandalam, and F. Damilano Loss of PI3Kgamma enhances camp-dependent mmp remodeling of the myocardial n-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress Circ Res 107 2010 1275 1289
25. E. Patrucco, A. Notte, L. Barberis, G. Selvetella, A. Maffei, and M. Brancaccio PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects Cell 118 2004 375 387
26. D.A. Fruman, S.B. Snapper, C.M. Yballe, L. Davidson, J.Y. Yu, and F.W. Alt Impaired b cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha Science 283 1999 393 397
27. A. Di Cristofano, B. Pesce, C. Cordon-Cardo, and P.P. Pandolfi PTEN is essential for embryonic development and tumour suppression Nat Genet 19 1998 348 355
28. P. Voigt, M.B. Dorner, and M. Schaefer Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3b J Biol Chem 281 2006 9977 9986
29. C. Brock, M. Schaefer, H.P. Reusch, C. Czupalla, M. Michalke, and K. Spicher Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma J Cell Biol 160 2003 89 99
30. J. Guillermet-Guibert, K. Bjorklof, A. Salpekar, C. Gonella, F. Ramadani, and A. Bilancio The p110beta isoform of phosphoinositide 3-kinase signals downstream of g protein-coupled receptors and is functionally redundant with p110gamma Proc Natl Acad Sci U S A 105 2008 8292 8297
31. S. Suire, A.M. Condliffe, G.J. Ferguson, C.D. Ellson, H. Guillou, and K. Davidson Gbetagammas and the Ras binding domain of p110gamma are both important regulators of Pi(3)Kgamma signalling in neutrophils Nat Cell Biol 8 2006 1303 1309
32. S. Gupta, A.R. Ramjaun, P. Haiko, Y. Wang, P.H. Warne, and B. Nicke Binding of Ras to phosphoinositide 3-kinase p110alpha is required for Ras-driven tumorigenesis in mice Cell 129 2007 957 968
33. D.R. Alessi, M. Deak, A. Casamayor, F.B. Caudwell, N. Morrice, and D.G. Norman 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase Curr Biol 7 1997 776 789
34. D.R. Alessi, S.R. James, C.P. Downes, A.B. Holmes, P.R. Gaffney, and C.B. Reese Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase balpha Curr Biol 7 1997 261 269
35. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKb by the RICTOR-mTOR complex Science 307 2005 1098 1101
36. X. Gan, J. Wang, B. Su, and D. Wu Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 286 2011 10998 11002
37. H. Sano, S. Kane, E. Sano, C.P. Miinea, J.M. Asara, and W.S. Lane Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation J Biol Chem 278 2003 14599 14602
38. G.V. Rayasam, V.K. Tulasi, R. Sodhi, J.A. Davis, and A. Ray Glycogen synthase kinase 3: more than a namesake Br J Pharmacol 156 2009 885 898
39. P.H. Sugden, S.J. Fuller, S.C. Weiss, and A. Clerk Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis Br J Pharmacol 153 Suppl 1 2008 S137 S153
40. D. Zhang, R. Contu, M.V. Latronico, J. Zhang, R. Rizzi, and D. Catalucci Mtorc1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice J Clin Invest 120 2010 2805 2816
41. R.S. Whelan, V. Kaplinskiy, and R.N. Kitsis Cell death in the pathogenesis of heart disease: mechanisms and significance Annu Rev Physiol 72 2010 19 44
42. M.C. Hollander, G.M. Blumenthal, and P.A. Dennis PTEN loss in the continuum of common cancers, rare syndromes and mouse models Nat Rev Cancer 11 2011 289 301
43. G.Y. Oudit, Z. Kassiri, J. Zhou, Q.C. Liu, P.P. Liu, and P.H. Backx Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress Cardiovasc Res 78 2008 505 514
44. H. Ruan, J. Li, S. Ren, J. Gao, G. Li, and R. Kim Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury J Mol Cell Cardiol 46 2009 193 200
45. J.M. Dyson, C.G. Fedele, E.M. Davies, J. Becanovic, and C.A. Mitchell Phosphoinositide phosphatases: just as important as the kinases Subcell Biochem 58 2012 215 279
46. J. Luo, J.R. McMullen, C.L. Sobkiw, L. Zhang, A.L. Dorfman, and M.C. Sherwood Class Ia phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy Mol Cell Biol 25 2005 9491 9502
47. K.L. Weeks, X. Gao, X.J. Du, E.J. Boey, A. Matsumoto, and B.C. Bernardo Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction Circ Heart Fail 5 2012 523 534
48. J.R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M.C. Sherwood, and P.M. Kang Phosphoinositide 3-kinas (p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy Proc Natl Acad Sci U S A 100 2003 12355 12360
49. I. Kehat, and J.D. Molkentin Molecular pathways underlying cardiac remodeling during pathophysiological stimulation Circulation 122 2010 2727 2735
50. S. Shah, C.P. Nelson, T.R. Gaunt, P. van der Harst, T. Barnes, and P.S. Braund Four genetic loci influencing electrocardiographic indices of left ventricular hypertrophy Circ Cardiovasc Genet 4 2011 626 635
51. J.R. McMullen, T. Shioi, W.Y. Huang, L. Zhang, O. Tarnavski, and E. Bisping The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinas (p110alpha) pathway J Biol Chem 279 2004 4782 4793
52. E.A. Jankowska, B. Biel, J. Majda, A. Szklarska, M. Lopuszanska, and M. Medras Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival Circulation 114 2006 1829 1837
53. J.R. McMullen, T. Shioi, W.Y. Huang, L. Zhang, O. Tarnavski, and E. Bisping The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway J Biol Chem 279 2004 4782 4793
54. Y.T. Tseng, N. Yano, A. Rojan, J.P. Stabila, B.G. McGonnigal, and V. Ianus Ontogeny of phosphoinositide 3-kinase signaling in developing heart: effect of acute beta-adrenergic stimulation Am J Physiol Heart Circ Physiol 289 2005 H1834 H1842
55. K.C. Yang, P.Y. Jay, J.R. McMullen, and J.M. Nerbonne Enhanced cardiac pi3kalpha signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure Cardiovasc Res 93 2012 252 262
56. Y. Inuzuka, J. Okuda, T. Kawashima, T. Kato, S. Niizuma, and Y. Tamaki Suppression of phosphoinositide 3-kinase prevents cardiac aging in mice Circulation 120 2009 1695 1703
57. B.T. O'Neill, J. Kim, A.R. Wende, H.A. Theobald, J. Tuinei, and J. Buchanan A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy Cell Metab 6 2007 294 306
58. N.C. Salazar, J. Chen, and H.A. Rockman Cardiac GPCRs: GPCR signaling in healthy and failing hearts Biochim Biophys Acta 1768 2007 1006 1018
59. S. Das, T. Aiba, M. Rosenberg, K. Hessler, C. Xiao, and P.A. Quintero Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling Circulation 126 2012 2208 2219
60. G.Y. Oudit, M.A. Crackower, U. Eriksson, R. Sarao, I. Kozieradzki, and T. Sasaki Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure Circulation 108 2003 2147 2152
61. J.D. Chang, G.K. Sukhova, P. Libby, E. Schvartz, A.H. Lichtenstein, and S.J. Field Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis Proc Natl Acad Sci U S A 104 2007 8077 8082
62. 3 and cAMP signaling through a PKA anchoring function of p110gamma Mol Cell 42 2011 84 95
63. B.G. Kerfant, D. Zhao, I. Lorenzen-Schmidt, L.S. Wilson, S. Cai, and S.R. Chen PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes Circ Res 101 2007 400 408
64. M. Siragusa, R. Katare, M. Meloni, F. Damilano, E. Hirsch, and C. Emanueli Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice Circ Res 106 2010 757 768
65. B.J. Haubner, G.G. Neely, J.G. Voelkl, F. Damilano, K. Kuba, and Y. Imai PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway PLoS One 5 2010 e9350
66. N.B. Ruderman, R. Kapeller, M.F. White, and L.C. Cantley Activation of phosphatidylinositol 3-kinase by insulin Proc Natl Acad Sci U S A 87 1990 1411 1415
67. S. Neubauer The failing heart - an engine out of fuel N Engl J Med 356 2007 1140 1151
68. H. Ashrafian, M.P. Frenneaux, and L.H. Opie Metabolic mechanisms in heart failure Circulation 116 2007 434 448
69. J.J. Zhao, H. Cheng, S. Jia, L. Wang, O.V. Gjoerup, and A. Mikami The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation Proc Natl Acad Sci U S A 103 2006 16296 16300
70. G.C. Smith, W.K. Ong, G.W. Rewcastle, J.D. Kendall, W. Han, and P.R. Shepherd Effects of acutely inhibiting PI3K isoforms and mtor on regulation of glucose metabolism in vivo Biochem J 442 2012 161 169
71. Z.A. Knight, B. Gonzalez, M.E. Feldman, E.R. Zunder, D.D. Goldenberg, and O. Williams A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling Cell 125 2006 733 747
72. G.M. Rosano, C. Vitale, M. Volterrani, and M. Fini Metabolic therapy for the diabetic patients with ischaemic heart disease Coron Artery Dis 16 Suppl 1 2005 S17 S21
73. G.D. Lopaschuk Metabolic abnormalities in the diabetic heart Heart Fail Rev 7 2002 149 159
74. B.A. McLean, P.C. Kienesberger, W. Wang, G. Masson, P. Zhabyeyev, and J.R. Dyck Enhanced recovery from ischemia-reperfusion injury in PI3Kalpha dominant negative hearts: investigating the role of alternate PI3K isoforms, increased glucose oxidation and MAPK signaling J Mol Cell Cardiol 54 2013 9 18
75. K. Walsh, and I. Shiojima Cardiac growth and angiogenesis coordinated by intertissue interactions J Clin Invest 117 2007 3176 3179
76. P. Carmeliet, and R.K. Jain Molecular mechanisms and clinical applications of angiogenesis Nature 473 2011 298 307
77. I. Shiojima, and K. Walsh Role of Akt signaling in vascular homeostasis and angiogenesis Circ Res 90 2002 1243 1250
78. J. Tang, J. Wang, X. Kong, J. Yang, L. Guo, and F. Zheng Vascular endothelial growth factor promotes cardiac stem cell migration via the PI3K/Akt pathway Exp Cell Res 315 2009 3521 3531
79. K.C. Yang, N.C. Foeger, C. Marionneau, P.Y. Jay, J.R. McMullen, and J.M. Nerbonne Homeostatic regulation of electrical excitability in physiological cardiac hypertrophy J Physiol 588 2010 5015 5032
80. 2+ currents via increased PI3Kalpha/PKB signaling Circ Res 98 2006 1390 1397
81. L. Pretorius, X.J. Du, E.A. Woodcock, H. Kiriazis, R.C. Lin, and S. Marasco Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation Am J Pathol 175 2009 998 1009
82. L.A. Blair, and J. Marshall IGF-1 modulates N and L calcium channels in a PI 3-kinase-dependent manner Neuron 19 1997 421 429
83. 2+-dependent positive inotropic effects in failing human myocardium Circ Res 92 2003 169 176
84. N. Macrez, C. Mironneau, V. Carricaburu, J.F. Quignard, A. Babich, and C. Czupalla Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular l-type Ca(2+) channels Circ Res 89 2001 692 699
85. L.M. Ballou, H.Y. Lin, G. Fan, Y.P. Jiang, and R.Z. Lin Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt J Biol Chem 278 2003 23472 23479
86. Y.K. Kim, S.J. Kim, A. Yatani, Y. Huang, G. Castelli, and D.E. Vatner Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed akt J Biol Chem 278 2003 47622 47628
87. M. Takano, and S. Kuratomi Regulation of cardiac inwardly rectifying potassium channels by membrane lipid metabolism Prog Biophys Mol Biol 81 2003 67 79
88. 2 with ion channels and transporters Sci STKE 2001 2001 re19
89. T. Rohacs, C.M. Lopes, T. Jin, P.P. Ramdya, Z. Molnar, and D.E. Logothetis Specificity of activation by phosphoinositides determines lipid regulation of Kir channels Proc Natl Acad Sci U S A 100 2003 745 750
90. + channels expressed in HEK293 cells requires basal protein kinase B activity FEBS Lett 534 2003 125 132
91. M.N. Andersen, S.P. Olesen, and H.B. Rasmussen Kv7.1 surface expression is regulated by epithelial cell polarization Am J Physiol Cell Physiol 300 2011 C814 C824
92. H.W. Shin, M. Hayashi, S. Christoforidis, S. Lacas-Gervais, S. Hoepfner, and M.R. Wenk An enzymatic cascade of rab5 effectors regulates phosphoinositide turnover in the endocytic pathway J Cell Biol 170 2005 607 618
93. A. Kumar, J. Redondo-Munoz, V. Perez-Garcia, I. Cortes, M. Chagoyen, and A.C. Carrera Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival Mol Cell Biol 31 2011 2122 2133
94. Z. Dou, M. Chattopadhyay, J.A. Pan, J.L. Guerriero, Y.P. Jiang, and L.M. Ballou The class ia phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy J Cell Biol 191 2010 827 843
95. A. Nakai, O. Yamaguchi, T. Takeda, Y. Higuchi, S. Hikoso, and M. Taniike The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress Nat Med 13 2007 619 624
96. S.A. Sturgeon, C. Jones, J.A. Angus, and C.E. Wright Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an antithrombotic agent devoid of other cardiovascular actions in the rat Eur J Pharmacol 587 2008 209 215
97. C.R. Zito, L.B. Jilaveanu, V. Anagnostou, D. Rimm, G. Bepler, and S.M. Maira Multi-level targeting of the phosphatidylinositol-3-kinase pathway in nonsmall cell lung cancer cells PLoS One 7 2012 e31331
98. L. Salmena, A. Carracedo, and P.P. Pandolfi Tenets of PTEN tumor suppression Cell 133 2008 403 414
99. N.R. Leslie, and M. Foti Nongenomic loss of PTEN function in cancer: not in my genes Trends Pharmacol Sci 32 2011 131 140
100. L. Zhao, and P.K. Vogt Class I PI3K in oncogenic cellular transformation Oncogene 27 2008 5486 5496
101. J. Shi, D. Yao, W. Liu, N. Wang, H. Lv, and G. Zhang Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer BMC Cancer 12 2012 50
102. A.J. Philp, I.G. Campbell, C. Leet, E. Vincan, S.P. Rockman, and R.H. Whitehead The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors Cancer Res 61 2001 7426 7429
103. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
104. L.C. Foukas, M. Claret, W. Pearce, K. Okkenhaug, S. Meek, and E. Peskett Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation Nature 441 2006 366 370
105. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627 644
106. J. Baselga Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer Oncologist 16 Suppl 1 2011 12 19
107. N. Miled, Y. Yan, W.C. Hon, O. Perisic, M. Zvelebil, and Y. Inbar Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit Science 317 2007 239 242
108. D. Mandelker, S.B. Gabelli, O. Schmidt-Kittler, J. Zhu, I. Cheong, and C.H. Huang A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane Proc Natl Acad Sci U S A 106 2009 16996 17001
109. K. Kalinsky, L.M. Jacks, A. Heguy, S. Patil, M. Drobnjak, and U.K. Bhanot PIK3CA mutation associates with improved outcome in breast cancer Clin Cancer Res 15 2009 5049 5059
110. L. Wang, Q. Zhang, J. Zhang, S. Sun, H. Guo, and Z. Jia PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib BMC Cancer 11 2011 248
111. E. Ciraolo, M. Iezzi, R. Marone, S. Marengo, C. Curcio, and C. Costa Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development Sci Signal 1 2008 ra3
112. S. Jia, Z. Liu, S. Zhang, P. Liu, L. Zhang, and S.H. Lee Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis Nature 454 2008 776 779
113. X. Jiang, S. Chen, J.M. Asara, and S.P. Balk Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits J Biol Chem 285 2010 14980 14989
114. Genetech. A dose escalation study evaluating the safety and tolerability of gdc-0032 in patients with locally advanced or metastatic solid tumors and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptorepositive breast cancer. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/show/NCT01296555. Accessed October 3, 2012.
115. Novartis. A study of BYL719 in adult patients with advanced solid malignancies. ClinicalTrials.gov. Available at: http://clinicaltrials.gov/show/ NCT01387321. Accessed October 3, 2012.
116. A.J. Folkes, K. Ahmadi, W.K. Alderton, S. Alix, S.J. Baker, and G. Box The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J Med Chem 51 2008 5522 5532
117. F.I. Raynaud, S.A. Eccles, S. Patel, S. Alix, G. Box, and I. Chuckowree Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Mol Cancer Ther 8 2009 1725 1738
118. S.M. Maira, S. Pecchi, A. Huang, M. Burger, M. Knapp, and D. Sterker Identification and characterization of nvp-bkm120, an orally available pan-class i pi3-kinase inhibitor Mol Cancer Ther 11 2012 317 328
119. D. Koul, J. Fu, R. Shen, T.A. LaFortune, S. Wang, and N. Tiao Antitumor activity of nvp-bkm120-a selective pan class i pi3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells Clin Cancer Res 18 2012 184 195
120. N.T. Ihle, R. Williams, S. Chow, W. Chew, M.I. Berggren, and G. Paine-Murrieta Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol Cancer Ther 3 2004 763 772
121. A. Chakrabarty, V. Sanchez, M.G. Kuba, C. Rinehart, and C.L. Arteaga Feedback upregulation of her3 (erbb3) expression and activity attenuates antitumor effect of pi3k inhibitors Proc Natl Acad Sci USA 109 2012 2718 2723
122. D. Kong, and T. Yamori ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms Cancer Sci 98 2007 1638 1642
123. S.M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, and C. Fritsch Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol Cancer Ther 7 2008 1851 1863
124. D. Roulin, L. Waselle, A. Dormond-Meuwly, M. Dufour, N. Demartines, and O. Dormond Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib Mol Cancer 10 2011 90
125. G. Prasad, T. Sottero, X. Yang, S. Mueller, C.D. James, and W.A. Weiss Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide Neuro Oncol 13 2011 384 392
126. O.K. Mirzoeva, B. Hann, Y.K. Hom, J. Debnath, D. Aftab, and K. Shokat Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma J Mol Med (Berl) 89 2011 877 889
127. T. Ozbay, D.L. Durden, T. Liu, R.M. O'Regan, and R. Nahta In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells Cancer Chemother Pharmacol 65 2010 697 706
128. J.R. Garlich, P. De, N. Dey, J.D. Su, X. Peng, and A. Miller A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res 68 2008 206 215
129. D.P. Sutherlin, L. Bao, M. Berry, G. Castanedo, I. Chuckowree, and J. Dotson Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer J Med Chem 54 2011 7579 7587
130. J.J. Wallin, K.A. Edgar, J. Guan, M. Berry, W.W. Prior, and L. Lee GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway Mol Cancer Ther 10 2011 2426 2436
131. K.Y. Chang, S.Y. Tsai, C.M. Wu, C.J. Yen, B.F. Chuang, and J.Y. Chang Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo Clin Cancer Res 17 2011 7116 7126
132. A.M. Venkatesan, C.M. Dehnhardt, E. Delos Santos, Z. Chen, O. Dos Santos, and S. Ayral-Kaloustian Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor J Med Chem 53 2010 2636 2645
133. M.E. Noble, J.A. Endicott, and L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805
134. L. Salphati, H. Wong, M. Belvin, D. Bradford, K.A. Edgar, and W.W. Prior Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor gdc-0941 Drug Metab Dispos 38 2010 1436 1442
135. H. Sun, G.Y. Oudit, R.J. Ramirez, D. Costantini, and P.H. Backx The phosphoinositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of ik, slow currents Cardiovasc Res 62 2004 509 520
136. C. Zhang, G. Habets, and G. Bollag Interrogating the kinome Nat Biotechnol 29 2011 981 983
137. K. Berns, H.M. Horlings, B.T. Hennessy, M. Madiredjo, E.M. Hijmans, and K. Beelen A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 2007 395 402
138. Novartis. A phase IB/II study of BEZ235 and trastuzumab in patients with HER2-positive breast cancer who failed prior to trastuzumab. 2012: NCT01471847.
139. B. Wadugu, and B. Kuhn The role of neuregulin/erbb2/erbb4 signaling in the heart with special focus on effects on cardiomyocyte proliferation Am J Physiol Heart Circ Physiol 302 2012 16
140. C.M. Taniguchi, B. Emanuelli, and C.R. Kahn Critical nodes in signalling pathways: insights into insulin action Nat Rev Mol Cell Biol 7 2006 85 96
141. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, and D. Smith mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508
142. S. Grant Cotargeting survival signaling pathways in cancer J Clin Invest 118 2008 3003 3006
143. M.E. Feldman, and K.M. Shokat New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of TOR kinase domain inhibitors (torkinibs) Curr Top Microbiol Immunol 347 2010 241 262
144. D.W. McMillin, M. Ooi, J. Delmore, J. Negri, P. Hayden, and N. Mitsiades Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 Cancer Res 69 2009 5835 5842
145. E. Yao, W. Zhou, S.T. Lee-Hoeflich, T. Truong, P.M. Haverty, and J. Eastham-Anderson Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab Clin Cancer Res 15 2009 4147 4156
146. C.A. Lovejoy, and D. Cortez Common mechanisms of PIKK regulation DNA Repair (Amst) 8 2009 1004 1008
147. S. Djordjevic, and P.C. Driscoll Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases Trends Biochem Sci 27 2002 426 432
148. B.A. McLean, P.C. Kienesberger, W. Wang, G. Masson, P. Zhabyeyev, and J.R. Dyck Enhanced recovery from ischemia-reperfusion injury in pi3kalpha dominant negative hearts: Investigating the role of alternate pi3k isoforms, increased glucose oxidation and mapk signaling J Mol Cell Cardiol 54 2013 9 18
149. B.A. Rose, T. Force, and Y. Wang Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale Physiol Rev 90 2010 1507 1546
150. V. Serra, M. Scaltriti, L. Prudkin, P.J. Eichhorn, Y.H. Ibrahim, and S. Chandarlapaty PI3K inhibition results in enhanced her signaling and acquired ERK dependency in HER2-overexpressing breast cancer Oncogene 30 2011 2547 2557
151. J. Chen, J.B. Long, A. Hurria, C. Owusu, R.M. Steingart, and C.P. Gross Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer J Am Coll Cardiol 60 2012 2504 2512
152. M.S. Ewer, D.D. von Hoff, and R.S. Benjamin A historical perspective of anthracycline cardiotoxicity Heart Fail Clin 7 2011 363 372
153. C. Schult, M. Dahlhaus, A. Glass, K. Fischer, S. Lange, and M. Freund The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts antiproliferative activity toward acute lymphoblastic leukemia cells Anticancer Res 32 2012 463 474
154. A. Seidman, C. Hudis, M.K. Pierri, S. Shak, V. Paton, and M. Ashby Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221
155. M.U. Yood, K.E. Wells, S.H. Alford, H. Dakki, A.B. Beiderbeck, and A. Hurria Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy Pharmacoepidemiol Drug Saf 21 2012 818 827
156. C. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, and L. Fehrenbacher First-line, single-agent herceptin (trastuzumab) in metastatic breast cancer: a preliminary report Eur J Cancer 37 Suppl 1 2001 S25 S29
157. V.H. Murthy, H.M. Krumholz, and C.P. Gross Participation in cancer clinical trials: race-, sex-, and age-based disparities JAMA 291 2004 2720 2726
158. T. Eschenhagen, T. Force, M.S. Ewer, G.W. de Keulenaer, T.M. Suter, and S.D. Anker Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
159. H. Cheng, G. Kari, A.P. Dicker, U. Rodeck, W.J. Koch, and T. Force A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity Circ Res 109 2011 1401 1409
160. H. Vidarsson, J. Hyllner, and P. Sartipy Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications Stem Cell Rev 6 2010 108 120
161. E.T. Yeh, A.T. Tong, D.J. Lenihan, S.W. Yusuf, J. Swafford, and C. Champion Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management Circulation 109 2004 3122 3131
162. R.L. Jones, C. Swanton, and M.S. Ewer Anthracycline cardiotoxicity Expert Opin Drug Saf 5 2006 791 809
163. E.T. Yeh, and C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231 2247
164. D. Wadhwa, N. Fallah-Rad, D. Grenier, M. Krahn, T. Fang, and R. Ahmadie Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study Breast Cancer Res Treat 117 2009 357 364
165. M.J. Haykowsky, J.R. Mackey, R.B. Thompson, L.W. Jones, and D.I. Paterson Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training Clin Cancer Res 15 2009 4963 4967
166. A. Yildirim, F.S. Tunaoglu, F.G. Pinarli, M. Ilhan, A. Oguz, and C. Karadeniz Tissue and flow myocardial performance index measurements taken during dobutamine stress echocardiography for early diagnosis of late anthracycline cardiotoxicity Pediatr Cardiol 31 2010 96 105
167. D. Cardinale, and C.M. Cipolla Assessment of cardiotoxicity with cardiac biomarkers in cancer patients Herz 36 2011 325 332
168. University of Alberta. Multidisciplinary team intervention in cardio-oncology (titan study). ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01621659. Accessed November 23, 2012.
169. M.J. Haykowsky, Y. Liang, D. Pechter, L.W. Jones, F.A. McAlister, and A.M. Clark A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed J Am Coll Cardiol 49 2007 2329 2336
170. J.M. Scott, A. Khakoo, J.R. Mackey, M.J. Haykowsky, P.S. Douglas, and L.W. Jones Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms Circulation 124 2011 642 650
171. M. Haykowsky, J. Scott, B. Esch, D. Schopflocher, J. Myers, and I. Paterson A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction: start early and go longer for greatest exercise benefits on remodeling Trials 12 2011 92
172. D.J. Glass PI3 kinase regulation of skeletal muscle hypertrophy and atrophy Curr Top Microbiol Immunol 346 2010 267 278
173. S. Antoun, L. Birdsell, M.B. Sawyer, P. Venner, B. Escudier, and V.E. Baracos Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study J Clin Oncol 28 2010 1054 1060
174. D. Cardinale, A. Colombo, M.T. Sandri, G. Lamantia, N. Colombo, and M. Civelli Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481
175. S. Seicean, A. Seicean, J.C. Plana, G.T. Budd, and T.H. Marwick Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study J Am Coll Cardiol 60 2012 2384 2390
176. E. Pituskin, M. Haykowsky, J.R. Mackey, R.B. Thompson, J. Ezekowitz, and S. Koshman Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI BMC Cancer 11 2011 318